Urate-lowering therapy in cardiovascular pharmacotherapy: from Mendelian randomization data to cardio–renal–metabolic risk modulation

European Heart Journal - Cardiovascular Pharmacotherapy · Published 2026-06-16 · DOI 10.1093/ehjcvp/pvag042

Free full text

Authors (3)

Claudio Borghi, Federica Fogacci, Arrigo F G Cicero

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Borghi, C., Fogacci, F., Cicero, A. (2026). Urate-lowering therapy in cardiovascular pharmacotherapy: from Mendelian randomization data to cardio–renal–metabolic risk modulation. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvag042

Related articles

• Hyperuricemia and prevention of cardiometabolic disease: Unexplored is not unexpected · European Journal of Internal Medicine · 2026 · Cites or is cited by this article
• Beta-blockers after myocardial infarction: time to change the guidelines · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Why does research integrity affect us all? · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Aspirin may take a back row seat for non-ST-segment elevation acute coronary syndrome after percutaneous coronary intervention · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Innovation and constraints in cardiovascular pharmacotherapy · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Why cardio-rheumatology? · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• VESALIUS keeps revolutionizing medicine: the case of evolocumab in primary prevention · European Heart Journal - Cardiovascular Pharmacotherapy · 2025 · Same journal
• Effect of beta blockers in acute and chronic coronary syndromes without reduced ejection fraction: a landmark analysis from the REBOOT trial · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Real-world evidence of finerenone in Type 2 diabetes: addressing confounding and follow-up duration · European Heart Journal - Cardiovascular Pharmacotherapy · 2025 · Same journal
• Different aspects of myocardial intervention and pharmacological treatment · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal